Latest Ratios: P/E Ratio -29.4x · EV/EBITDA N/A · ROE -14.2%. (2015–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $474M | $484M | $253M | $25M | $151M | $200M | $335M | $879M | — | — | — |
| Enterprise Value | $412M | $422M | $207M | $17M | $143M | $180M | $319M | $866M | — | — | — |
| P/E Ratio → | -29.40 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 3.80 | 3.51 | 4.59 | 4.41 | 14.94 | 10.57 | 21.37 | 69.59 | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -14.2% | -14.2% | -51.4% | -107.2% | -72.4% | -52.6% | -44.5% | -43.2% | -39.0% | -265.9% | -42.5% |
| ROA | -13.6% | -13.6% | -46.1% | -81.7% | -62.3% | -48.7% | -41.7% | -40.9% | -37.4% | -258.1% | -41.4% |
| ROIC | -29.4% | -29.4% | -321.4% | -5671.9% | -2878.6% | — | — | — | -769.7% | -1784.1% | -118.7% |
| ROCE | -17.3% | -17.3% | -53.3% | -112.6% | -72.6% | -52.7% | -46.0% | -44.2% | -41.2% | -266.7% | -42.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | — | — | 0.00 | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.45 | -0.83 | -1.30 | -0.81 | -1.07 | -1.07 | -1.05 | -1.00 | -0.93 | -0.73 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -32.27 | -343.07 | -163.83 |
Net cash position: cash ($62M) exceeds total debt ($154920)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 51.35 | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.32 | 29.28 | 32.48 |
| Quick Ratio | 51.35 | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 | 14.28 | 18.27 | 18.32 | 29.28 | 32.48 |
| Cash Ratio | 51.33 | 51.33 | 11.46 | 4.13 | 4.19 | 12.85 | 14.22 | 18.25 | 17.25 | 28.80 | 32.13 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 7.4% | 7.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 7.4% | 7.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $7M | $11M | $15M | $13M | $12M | $11M | $11M | $10M | $10M | $10M |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MNPR stock.
Monopar Therapeutics Inc.'s current P/E ratio is -29.4x. This places it at the 50th percentile of its historical range.
Monopar Therapeutics Inc.'s return on equity (ROE) is -14.2%. The historical average is -68.9%.
Based on historical data, Monopar Therapeutics Inc. is trading at a P/E of -29.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Finite cash runway without revenue
Metrics are mathematically derived from official filings.
Negative Earnings Leave P/E Uninformative
With trailing P/E at -29.92 and a P/B of 3.87 against a pre-revenue cost base, reported figures suggest the market is pricing MNPR on its clinical pipeline rather than on earnings or book value.
A negative P/E is not meaningful as a valuation anchor, so the 3.87 P/B becomes the more informative multiple, though book value here is largely cash that is being consumed at roughly $6M per quarter. Compared with its own history and the sampled peers, the premium to book appears to reflect option value on MNPR-101 and Validive rather than any earnings base. Investors should treat the multiple as contingent on clinical readouts and monitor whether book value erodes faster than the market's implied pipeline value.
Losses Persist With No Revenue Offset
Gross, operating, and net margins are unavailable because MNPR reports zero revenue, while ROE of -4.8% and ROA of -4.7% in 2026Q3 show continuing losses against a small equity base.
The absence of revenue means margin analysis cannot distinguish earning power from cost structure, so the return metrics are the only usable profitability signal. ROE has improved from roughly -36% in 2024Q4 to near -4% in recent quarters, but this reflects a larger equity base rather than operating improvement, as net losses remain around $6M per quarter. The trajectory suggests the loss rate is stable, and sustainability depends on whether funding persists long enough for pipeline catalysts.
ROIC Turning Less Negative Recently
ROIC moved from -22.9% in 2025Q3 to -4.9% in 2026Q1 and -7.3% in 2026Q3, indicating that invested capital is being consumed at a slower rate than in 2025, though returns remain deeply negative.
The improvement in ROIC appears driven more by a larger invested capital base than by any reduction in losses, which is consistent with the balance sheet expansion seen in 2025. Peer ROIC values vary widely, with CLDX at -35.2% and NKTR at -57.2%, so MNPR's recent figures sit toward the less-negative end of the clinical-stage group. Based on these reported figures, the metric is best read as evidence of capital preservation rather than value creation until revenue exists.
Current Ratio Overstates Cushion
A current ratio of 43.55 in 2026Q3 is driven almost entirely by cash, which has fallen from $61.8M at year-end 2025 to $52.6M, against quarterly operating burn of roughly $6M.
The headline liquidity ratio is extreme because MNPR holds almost no operating liabilities, so it reflects cash concentration rather than operating strength. Quick and current ratios are identical given the lack of inventory, meaning liquidity analysis reduces to cash divided by burn. At the current burn rate the reported cash position implies a finite runway of several years at most, which appears to make future equity financing a probable requirement, though this is an inference from reported figures rather than a disclosed plan.
Current Ratio Misleads on Runway
The most commonly misapplied ratio for a pre-revenue biotech is the current ratio, which at 43.55 suggests strength while obscuring that cash burn, not working capital, determines survival.
Analysts often read a high current ratio as evidence of financial health, but for a company with no revenue and no inventory it simply reflects that nearly all assets are cash awaiting consumption by trials. A more appropriate measure is cash runway, calculated as cash divided by the trailing quarterly operating burn, alongside net cash per share. Investors should monitor the runway figure and any shift toward dilutive financing, since the reported liquidity ratio alone does not indicate how long the cash lasts.